T3D-959

T3D-959 (DB-959, DB-959Na as the sodium salt) is an orally bioavailable, brain-penetrant, non-thiazolidinedione dual agonist of peroxisome proliferator-activated receptor delta (PPARd; human ED50 19 nM) and peroxisome proliferator-activated receptor gamma (PPARg; human ED50 297 nM), conferring approximately 15-fold selectivity for the delta isoform. The compound was originally synthesized by Bayer and advanced through Phase 1 clinical trials for dyslipidemia and type 2 diabetes by DARA BioSciences before being acquired in 2013 by T3D Therapeutics and repositioned as a disease-modifying candidate for Alzheimer's disease (AD) on the basis of the "type 3 diabetes" hypothesis, which posits that sporadic AD is driven by progressive brain insulin resistance, deficient insulin and insulin-like growth factor signaling, and consequent neurometabolic dysfunction. T3D-959 is the first PPARd-activating compound to enter clinical development for AD and represents a mechanistically distinct approach from the anti-amyloid antibody and cholinesterase inhibitor classes that dominate the current AD therapeutic landscape. Preclinical characterization in the intracerebral streptozotocin (i.c. STZ) rat model of sporadic AD, conducted principally by the de la Monte laboratory at Brown University, demonstrated that oral T3D-959 at doses of 0.3 to 3.0 mg/kg/day preserved spatial learning and memory in the Morris water maze, prevented brain weight loss, normalized phosphorylated tau and amyloid precursor protein-amyloid beta 42 (AbPP-Ab42) levels, reduced markers of oxidative stress, and partially restored cholinergic enzyme expression and white matter integrity. Therapeutic effects were observed even when treatment was delayed seven days after the STZ insult, suggesting relevance to mild and moderate disease stages. A separate preclinical study demonstrated that T3D-959 at 1.0 mg/kg/day improved motor function and prevented cerebellar white matter atrophy in the same model. An exploratory Phase 2a clinical trial in 36 subjects with mild to moderate AD (Chamberlain et al. 2020) demonstrated safety and tolerability at oral doses of 3, 10, 30, and 90 mg daily for 14 days, with no serious adverse events. Pharmacokinetic analysis confirmed dose-dependent systemic exposure exceeding the PPARd ED50 at all doses tested. Plasma metabolomics showed dose-dependent reductions in branched-chain amino acids and ceramides and increases in acylcarnitines, consistent with improved insulin sensitivity and enhanced fatty acid beta-oxidation. FDG-PET neuroimaging demonstrated dose-dependent increases in regional cerebral glucose metabolism, with the strongest effects in the putamen, anterior cingulate, insula, and orbital frontal cortex. Cognitive assessments showed improvements on the ADAS-Cog11 at 30 mg and on the Digit Symbol Substitution Test at all doses, with a delayed improvement pattern consistent with a transcriptional regulatory mechanism of action and an apparent ApoE4 genotype interaction. The Phase 2 PIONEER trial, a 24-week multicenter randomized double-blind placebo-controlled study in 250 patients with mild to moderate AD, reported positive top-line results in November 2023 at the 16th Clinical Trials on Alzheimer's Disease (CTAD) conference. In the modified intent-to-treat population (n=141), the 30 mg group showed improvement on ADAS-Cog11 (0.73 versus 2.70 on placebo; p=0.073), and the 15 mg group showed improvement on ADCS-CGIC (0.39 versus 0.86 on placebo; p=0.060). Plasma amyloid beta 42/40 ratio improved significantly in the 30 mg (p=0.011) and 45 mg (p=0.033) groups, and the neurodegeneration marker neurogranin improved significantly in the 30 mg group (p=0.035). The compound was well tolerated, with adverse event rates similar between active and placebo arms (37.3% versus 43.1%) and no treatment-related serious adverse events. A Phase 2b/3 trial (NCT06964230) at 30 mg daily for 78 weeks in approximately 376 patients with biomarker-validated mild to moderate AD is planned to initiate in 2026. T3D-959 is not approved for any indication in any jurisdiction. This monograph reviews the chemistry, dual-receptor pharmacology, preclinical evidence base, clinical development program, pharmacokinetics, sourcing, reconstitution, stack interactions, adverse-event signal, and a comparative assessment of five alternative PPAR-targeting and insulin-sensitizing candidates against T3D-959 on five competency standards.